Musculoskeletal Matters 6 | Page 2

CO-PROXAMOL • I  n Jan 2005, MHRA advised to stop using •  Co-proxamol use declined significantly at this time co-proxamol due to linked high fatality rates (Figure 2) and was replaced with alternative involving both intentional and accidental overdose. paracetamol and opioid combination analgesics with similar painkilling effect. Figure 2: Changes in North Staffordshire co-proxamol and combination analgesic prescribing 2002-2009 quarter moderate analgesics moderate analgesics excl. coproxamol coproxamol Moderate analgesics include codeine 15mg, nefopam, buprenorphine (200mcg tablets or 5 -10mcg/hr patches), dihydrocodeine 20mg alone or in combination with paracetamol. TOPICAL NSAIDs • I  n Feb 2008, NICE osteoarthritis (OA) guidelines encouraged topical NSAID use. • T  he upward trend in prescriptions of topical NSAIDs prior to 2008 increased significantly after the guidelines were published (Figure 3). Figure 3: Changes in North Staffordshire topical NSAID prescribing 2002-2009 quarter topical NSAIDS Safe prescribing is achievable if key guidance is integrated into local prescribing policy. Useful links: MHRA (www.mhra.gov.uk/); NICE OA Guidelines (www.nice.org.uk/cg59) All figures reproduced with permission from Bedson J et al. The effectiveness of national guidance in changing analgesic prescribing in primary care from 2002 to 2009: an observational database study, European Journal of Pain, 2013;17:434-443. For more information visit: www.keele.ac.uk/pchs/disseminatingourresearch/newslettersandresources/bulletins